Trial Profile
Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cetuximab; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 03 Oct 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Sep 2025.
- 13 Apr 2021 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.